115 related articles for article (PubMed ID: 25001144)
21. [Protective effects of Lovastatin on early diabetic renal tissue and the possible mechanism].
Wang LH; Duan HJ; Shi YH; Liu QJ
Wei Sheng Yan Jiu; 2005 Jan; 34(1):70-3. PubMed ID: 15862029
[TBL] [Abstract][Full Text] [Related]
22. [Prevention and remission of diabetic nephropathy].
Sugimoto T; Nakamura Y; Makino H
Nihon Rinsho; 2003 Jul; 61(7):1167-71. PubMed ID: 12877079
[TBL] [Abstract][Full Text] [Related]
23. Uremia (end-stage renal disease): how cost-effective are preventive strategies?
Glassock RJ
J Ren Nutr; 2010 Sep; 20(5 Suppl):S131-4. PubMed ID: 20797562
[TBL] [Abstract][Full Text] [Related]
24. Insulin therapy in renal disease.
Iglesias P; Díez JJ
Diabetes Obes Metab; 2008 Sep; 10(10):811-23. PubMed ID: 18248491
[TBL] [Abstract][Full Text] [Related]
25. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
Tobert JA
Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
[TBL] [Abstract][Full Text] [Related]
26. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
Guijarro C; Keane WF
Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
[TBL] [Abstract][Full Text] [Related]
27. [Microinflammation in the pathogenesis of diabetic nephropathy].
Shikata K
Nihon Jinzo Gakkai Shi; 2007; 49(5):474-80. PubMed ID: 17695807
[No Abstract] [Full Text] [Related]
28. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR
Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662
[TBL] [Abstract][Full Text] [Related]
29. Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid.
Collidge TA; Razvi S; Nolan C; Whittle M; Stirling C; Russell AJ; Mann AC; Deighan CJ
Diabet Med; 2010 Jun; 27(6):696-700. PubMed ID: 20546290
[TBL] [Abstract][Full Text] [Related]
30. Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?
Velasquez MT; Ramezani A; Raj DS
Kidney Int; 2015 Jun; 87(6):1092-4. PubMed ID: 26024026
[TBL] [Abstract][Full Text] [Related]
31. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
32. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
[TBL] [Abstract][Full Text] [Related]
33. Nephropathy and other topics.
Bloomgarden ZT
Diabetes Care; 2009 Aug; 32(8):e94-8. PubMed ID: 19638520
[No Abstract] [Full Text] [Related]
34. [Kidney and statins].
Moulin B; Caillard S
Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):121-7. PubMed ID: 11240414
[TBL] [Abstract][Full Text] [Related]
35. Lipids and progressive renal failure.
Keane WF
Wien Klin Wochenschr; 1996; 108(14):420-4. PubMed ID: 8784983
[TBL] [Abstract][Full Text] [Related]
36. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
37. Lovastatin and sudden unexpected death in epilepsy: a matter for debate.
Nejm MB; Gouveia TL; da Graça Naffah-Mazacoratti M; Scorza CA; Cavalheiro EA; Scorza FA
Epilepsy Behav; 2013 Jul; 28(1):10-1. PubMed ID: 23648273
[No Abstract] [Full Text] [Related]
38. Renewed interest in lovastatin following launch of Lovachol.
Cardiovasc J S Afr; 2005; 16(1):67. PubMed ID: 15778783
[No Abstract] [Full Text] [Related]
39. [Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
Faller J; Hess B
Praxis (Bern 1994); 2002 May; 91(19):836-44. PubMed ID: 12071084
[TBL] [Abstract][Full Text] [Related]
40. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Baba T; Neugebauer S; Watanabe T
Drugs; 1997 Aug; 54(2):197-234. PubMed ID: 9257079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
